Lung cancer has many threads.
This November marks #lungcancerawarenessmonth. In our latest blog, we take a closer look at 5 threads that shape the complexity of lung cancer and why they matter to drive innovation in lung cancer care.
🔗 www.biontech.com/int/en/home/media/blog/lung-cancer-aware…
BioNTech
BioNTech SE ( bee-ON-tek; or bye-ON-tek short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases. More on Wikipedia
-
BioNTech SE
@BioNTech_Group
-
BioNTech SE
@BioNTech_Group
Today, at #esmo26 we presented together with @bmsnews first global Phase 2 data in previously treated metastatic non-small cell lung cancer
🔗 www.biontech.com/int/en/home/mediaroom/news/press-release…
#biontech #oncologyresearch -
BioNTech SE
@BioNTech_Group
#biontech News: We have entered a clinical trial collaboration with Gilead to evaluate our investigational PD-L1×VEGF-A bispecific plus their TROP2 antibody-drug conjugate in a Phase 3 advanced triple-negative breast cancer trial.
Read more: www.biontech.com/int/en/home/mediaroom/news/press-release… -
BioNTech SE
@BioNTech_Group
At #esmo26, #biontech shares 16 abstracts across 10 tumor types. Highlights: late-breaking oral presentation of first data from ROSETTA Lung-107 for an investigational PD-L1×VEGF bispecific+chemotherapy in 2L mNSCLC, and novel IO+ADC combination data.
🔗 www.biontech.com/int/en/home/mediaroom/news/press-release… -
BioNTech SE
@BioNTech_Group
🎗 Not every breast cancer journey looks the same.
For people living with metastatic breast cancer, treatment can become part of everyday life and options may change over time.
Here are 5 reasons why continued research matters, during #breastcancerawarenessmonth and every day.
BioNTech SE
@BioNTech_Group
Read more 🔗: www.biontech.com/int/en/home/media/blog/breast-cancer-awa…
-
BioNTech SE
@BioNTech_Group
Lung cancer is not one disease.
Following #wclc26, Dr.@StephenVLiu reflects on the complexity of lung cancer, how our understanding has evolved and why different strategies need to be explored to address the needs that remain.
Watch 👇
#lungcancer #cancerresearch -
BioNTech SE
@BioNTech_Group
📢 Oncology news in 2L+ sqNSCLC: We presented the first median overall survival data from the PRESERVE-003 Phase 3 trial for a chemotherapy-free CTLA-4-targeting immunotherapy in 2L+ squamous non-small cell lung cancer.
🔗 Learn more: www.biontech.com/int/en/home/mediaroom/news/press-release…
#lungcancer #wclc26 -
BioNTech SE
@BioNTech_Group
We are excited to share new clinical data from our diversified lung cancer pipeline, including the first combination data for any PD-(L)1xVEGF bispecific plus a B7H3 ADC in lung cancer.
🔗 Learn more: www.biontech.com/int/en/home/mediaroom/news/press-release…
#lungcancer #oncology #wclc26 #biontechPost not available here, view on X
BioNTech SE
@BioNTech_Group
BioNTech SE
@BioNTech_Group
-
BioNTech SE
@BioNTech_Group
📢 𝗤𝟮 𝟮𝟬𝟮𝟲 𝗲𝗮𝗿𝗻𝗶𝗻𝗴𝘀 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗮𝗻𝗱 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 𝘂𝗽𝗱𝗮𝘁𝗲
𝗟𝗶𝗻𝗸 𝘁𝗼 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 𝗮𝗻𝗱 𝗳𝗼𝗿𝘄𝗮𝗿𝗱-𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘀𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀:
www.biontech.com/int/en/home/mediaroom/news/press-release…
BioNTech SE
@BioNTech_Group
Photo copyright Guido Oelkers: Sobi - Swedish Orphan Biovitrum AB (publ), 2026
-
BioNTech SE
@BioNTech_Group
We are building for the many within lung cancer. Through 16+ clinical trials, we are pursuing innovative therapeutic approaches across subtypes and biomarkers to advance progress where patients still need more.
Explore the many: www.biontech.com/int/en/home/research-and-innovation/ther…
#worldlungcancerday -
BioNTech SE
@BioNTech_Group
At #asco26, we presented interim data from the global Phase 2/3 ROSETTA Lung-02 clinical trial evaluating an investigational PD-L1 x VEGF-A bispecific immunomodulator in 1L squamous and non-squamous #nsclc.
-
BioNTech SE
@BioNTech_Group
At #sgoam26 we are presenting data from the largest trial to date to report results for a HER2-targeted ADC in recurrent HER2-expressing endometrial cancer.
Read more: investors.biontech.de/de/news-releases/news-release-detai…
#biontech #womenscancer #gynecologiconcology -
BioNTech SE
@BioNTech_Group
Tomorrow at #elcc26, Dr. Kai He will share data from stage 1 of the global Phase 3 PRESERVE-003 clinical trial evaluating a tumor microenvironment-selective regulatory T cell depletion candidate targeting CTLA-4 in second-line or later therapy of squamous NSCLC.
BioNTech SE
@BioNTech_Group
The candidate is being developed by BioNTech and OncoC4.
Join the proffered paper session at 3:35 pm CET in Auditorium A1. -
BioNTech SE
@BioNTech_Group
Tomorrow at #elcc26, @bensolomon1 will share the global Phase 2/3 ROSETTA Lung-02 trial design evaluating a PD-L1xVEGF-A bispecific immunomodulator plus chemotherapy in first-line non-small cell lung cancer (NSCLC).The candidate is being developed by BioNTech and @bmsnews
BioNTech SE
@BioNTech_Group
Join the poster session at 1:00 pm CET in the Foyer.
-
BioNTech SE
@BioNTech_Group
At the #elcc2026, we will present new clinical data from our late-stage portfolio across various #lungcancer subtypes and lines of treatment, reinforcing the transformative potential of our treatment approaches in this critical area.
👉investors.biontech.de/news-releases/news-release-details/…
#nsclc #esclcPost not available here, view on X
BioNTech SE
@BioNTech_Group
BioNTech SE
@BioNTech_Group
-
BioNTech SE
@BioNTech_Group
📢 JPM 2026|Strategic areas of focus
Oncology milestones in 2026:
- 7 late-stage data readouts
- 6 Phase 3 clinical trial initiations expected
- Focus on high-incidence indications, such as lung and breast cancer
📰 investors.biontech.de/events/event-details/44th-annual-jp…
🎥 investors.biontech.de/events/event-details/44th-annual-jp…
#jpm2026 -
BioNTech SE
@BioNTech_Group
Tomorrow at #sabcs25, Dr. Schmid will share the study design of the global phase 3 ROSETTA Breast-01 trial evaluating a PD-L1 x VEGF-A bispecific antibody plus chemotherapy in PD-L1 negative TNBC.
Join the poster session at 12:30pm CST in Exhibit Hall. -
BioNTech SE
@BioNTech_Group
🔬 At #sabcs25, we shared interim global Phase 2 data from our investigational bispecific antibody program in metastatic #tnbc with our partner @bmsnews
Learn more in our press release: investors.biontech.de/news-releases/news-release-details/…
#breastcancerresearch #oncologyscience #biontech -
BioNTech SE
@BioNTech_Group
Tomorrow at #sabcs25, Dr. Schmid will present preliminary data from a global multicohort phase 2 trial of a PD-L1 x VEGF-A bispecific antibody plus chemotherapy for 1L/2L+ locally advanced/metastatic TNBC.
-
BioNTech SE
@BioNTech_Group
Today, together with OncoC4, we announced data on an investigational selective Treg modulator candidate in patients with advanced sqNSCLC.
Learn more in our press release: investors.biontech.de/news-releases/news-release-details/…
#lungcancer #naclc25 -
BioNTech SE
@BioNTech_Group
Global interim Phase 2 data in extensive-stage small cell lung cancer presented at #wclc25:
Investigational approach designed to target PD-L1 and VEGF-A in a single molecule.
Full PR: investors.biontech.de/news-releases/news-release-details/… -
BioNTech SE
@BioNTech_Group
Small cell lung cancer is a key focus at #biontech with multiple trials across disease stages. At #wclc25, we share global interim Phase 2 data on our PD-L1xVEGF-A bispecific antibody candidate in extensive-stage small cell lung cancer.
BioNTech SE
@BioNTech_Group
Visit us at Booth #106.
-
BioNTech SE
@BioNTech_Group
We are partnering with @bmsnews to jointly develop and commercialize our PD-L1xVEGF bispecific #antibody candidate BNT327. Combining our expertise, resources, and global reach, we aim to bring novel combination therapies to patients with #cancer. 🚀 investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
At #biontech, we’re looking forward to #asco25, presenting oncology pipeline progress: mRNA cancer immunotherapies, ADCs, and next-gen immunomodulators and targeted therapies.
🗓 May 30 – June 3 | Chicago
📍 Booth #35165
#cancerresearch #immunooncology #oncologyinnovation
BioNTech SE
@BioNTech_Group
🔗 Highlights of our oncology programs to be presented at ASCO: investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Today, we shared our Q1 2025 results and updates on our business & pipeline. We also shared the news on a leadership transition: Jens Holstein will retire as planned and hand over the #newcfo role to Ramón Zapata as of July 1. Thank you, Jens! And welcome, Ramón Zapata. #biontech
BioNTech SE
@BioNTech_Group
🔗 Read more about our Q1 updates (including our forward-looking statements): investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
At #aacr25, we will present data from our #mrna and immuno-oncology priority programs. These data support execution of our combination strategy in oncology, including first data on the novel combination of our PD-L1xVEGF-A antibody candidate in combination with #adcs.
BioNTech SE
@BioNTech_Group
Explore more about the data: investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We aim to tackle one of the most lethal cancers worldwide: #lungcancer. This week, we are joining the global community at the #elcc25 presenting new data for our PD-L1/VEGF-A bispecific antibody candidate in metastatic #sclc. 👉Learn more about the data: investors.biontech.de/encrypted-node/8446
-
BioNTech SE
@BioNTech_Group
🚀 Update: We completed the acquisition of Biotheus. This strengthens our capabilities to develop, manufacture and commercialize next-gen bispecific antibodies, including BNT327 (PD-L1xVEGF-A bispecific), and supports the global execution of our oncology strategy.
BioNTech SE
@BioNTech_Group
👉Link to PR and forward-looking statements disclaimer: investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We are excited to be attending this year’s #sabcs24, with new interim Phase 1b/2 data for our anti-PD-L1/VEGF-A bispecific antibody candidate BNT327/PM8002 in triple-negative #breastcancer (#tnbc). 📍Visit us at booth # 226 to explore the latest data for this asset.
BioNTech SE
@BioNTech_Group
📊 Interim Ph1b/2 data for anti-PD-L1/VEGF-A bispecific antibody candidate BNT327 show a 73.8% cORR and a manageable safety profile (primary endpoints) with a mature 18-month OS rate of 69.7% (secondary endpoint) in 1L TNBC at #sabcs24. 👉 Find out more: investors.biontech.de/static-files/91989a40-9177-4d07-82e…
-
BioNTech SE
@BioNTech_Group
Advancing our oncology strategy: by strengthening next-gen immuno-modulator capabilities, we’re enhancing one core pillar of our oncology strategy.With investigational assets like BNT327/PM8002,our pipeline aims to build a new backbone in immuno-oncology.investors.biontech.de/de/news-releases/news-release-detai…
-
BioNTech SE
@BioNTech_Group
We are excited to present updates for our #oncology pipeline at #esmo24. Presentations feature candidates across multiple modalities which are important backbones for our combination treatment strategy & may open up new synergistic mechanisms of action.👉investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We have just announced that our personalized #mrna candidate BNT111 met its primary endpoint in randomized Ph 2 trial, demonstrating a statistically significant improvement in ORR in patients with anti-PD1 refractory/resistant #melanoma. 👉Read more: investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
The @US_FDA granted Fast Track designation for our #adc candidate BNT324/DB-1311 for the treatment of castration-resistant #prostatecancer. With this, all 3 clinical ADC candidates in our collab with #dualitybio have received Fast Track designation. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Visit our booth # 16153 at #asco2024 to learn about our progress in developing innovative potential therapeutic options for #cancer patients. Find an overview of our presentations: investors.biontech.de/news-releases/news-release-details/…
BioNTech SE
@BioNTech_Group
🔍 Initial Ph. 2 data for GEN1046/BNT311, a next-gen bispecific #antibody candidate jointly developed with @Genmab, showing 12 mo. overall survival rate of 69% when combined with pembrolizumab in PD-L1 pos. #mnsclc patients. Learn more: investors.biontech.de/news-releases/news-release-details/…
BioNTech SE
@BioNTech_Group
📊 Clinical trial data presentation for programs from our immuno-oncology pipeline & real-world data from 2 observational trials. 👉Explore our updates: investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We are excited to present updates for programs of our #oncology pipeline at the #asco24. This year’s data will be informing the direction of further development of several priority product candidates as well as the design of planned pivotal trials. 👉investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We have just announced 3-year Ph1 follow-up data for our individualized #mrna cancer vaccine candidate autogene cevumeran (BNT122) showing a persistent immune response and delayed tumor recurrence in some patients with resected #pdac. #aacr24
Find out more about the results⬇️Post not available here, view on X
BioNTech SE
@BioNTech_Group
Three-year follow-up data show: >80% of neoantigen-specific T cells induced by autogene cevumeran (BNT122) could still be detected up to 3 years post treatment in patients who responded to the investigational treatment, associated with delayed tumor recurrence. #aacr24 #oncology
BioNTech SE
@BioNTech_Group
Ph1 data show: Of those patients that responded, 98% of the T cells targeting individual neoantigens on the tumor and induced by autogene cevumeran (BNT122), an individualized mRNA cancer vaccine candidate, were not detected prior to treatment. Read more: investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We look forward to presenting updates for selected #mrna and #adc #oncology candidates at the @AACR Annual Meeting 2024. This year’s data show how we’re delivering on our commitment of investigating novel treatment approaches to patients. #aacr2024
👉investors.biontech.de/news-releases/news-release-details/… -
BioNTech SE
@BioNTech_Group
We presented a positive data update for our #cartcell therapy candidate BNT211 in advanced solid tumors at @myESMO Congress 2023. Our goal is to help improve the outcomes for a broad range of hard-to-treat tumors. Read more about the data update here: investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We announced today that the first patient has been treated in a #pdac Ph2 clinical trial with our individualized #mrna cancer immunotherapy candidate autogene cevumeran. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We are excited to present updates for five of our clinical candidates across our oncology pipeline at the 2023 @myESMO Congress. They underline the potential of our precision medicine toolkit for the treatment of solid tumors with high unmet medical need. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We applaud @kkariko and Drew Weissman on their #nobelprize in Physiology or Medicine for pioneering nucleoside base modifications which were one of the key innovations applied to our #mrna-based COVID-19 vaccine. Gratulálunk and congrats!
-
BioNTech SE
@BioNTech_Group
BioNTech has always been deeply rooted in academia. #stem grads can now explore #science projects and apply for a full-time contract via our ATLAS #phd program, a collab with TRON. Students with a sweet spot for #biomedical #research can apply by Oct 31. atlas-phdprogram.com/how-to-apply
-
BioNTech SE
@BioNTech_Group
We are pleased to announce our strategic partnership with @CEPIvaccines to advance the development of our #mrna based BNT166 #vaccine program for the prevention of mpox. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
The @US_FDA just approved our Omicron XBB.1.5-adapted COVID-19 vaccine for individuals 12+ years & granted emergency use for individuals 6 month through 11 years. The updated vaccine will be available at pharmacies, hospitals & clinics across the US soon. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
The @EMA_News’ Committee for Medicinal Products for Human Use recommended marketing authorization of our XBB.1.5-adapted #covid-19 vaccine. Following approval by the EC, the updated vaccine will be ready to ship to applicable EU member states immediately. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
#biontech expands its Management Board by appointing James Ryan as Chief Legal Officer. James will lead the legal strategy & global legal operations, contributing to BioNTech's success and growth trajectory in its mission to develop innovative #medicines. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We enter H2/2023 with a strong financial position and have submitted applications for a variant adapted #covid-19 vaccine to authorities. We aim to become a multi-product company by investing in our own clinical programs and adding compounds from partners. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Welcome @instadeepai to BioNTech! The acquisition supports our strategy, aiming to build world-leading capabilities in #ai-driven drug discovery and development of next-gen #immunotherapies and vaccines to address diseases with high unmet medical need. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We are pleased to be an integral part of this long-term partnership. First patients are expected to be treated in 2023 with the majority being enrolled from 2026+. We aim to improve outcomes for patients and broaden access to innovative immunotherapies in the UK and worldwide.
Department of Health and Social Care
@DHSCgovuk
✍️ We've signed an agreement with @BioNTech_Group to provide up to 10,000 NHS patients with ground-breaking new cancer treatments by 2030.
@NHSEngland and @GenomicsEngland will help to identify those eligible for personalised cancer vaccine trials. -
BioNTech SE
@BioNTech_Group
Today, the first patient has been treated in a pivotal Ph3 trial evaluating our antibody candidate BNT316/ONC-392 in #nsclc, jointly developed with OncoC4. We are committed to rapidly advancing our #oncology pipeline towards late-stage development. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We have concluded our AGM 2023. Baroness Nicola Blackwood will succeed Christoph Huber on the Supervisory Board. Michael Motschmann & Ulrich Wandschneider have been reappointed. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
In Q1/2023, we expanded our toolkit of cutting-edge technologies to new modalities and added novel oncology candidates to our pipeline. Our aim is to provide therapeutic benefits for cancer patients along the entire treatment journey. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE reposted
The Telegraph
@Telegraph
🔎 Why the company behind the Pfizer-BioNTech is rolling out a global network of portable vaccine factories
www.telegraph.co.uk/global-health/science-and-disease/ike… -
BioNTech SE
@BioNTech_Group
New assets to complement our oncology portfolio: Antibody-Drug Conjugates. We have entered into exclusive license and collaboration agreements with DualityBio for 2 investigational ADCs directed against targets expressed in a broad range of human cancers. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Today, we released our full year and Q4 results for the financial year 2022 – a year in which we made significant progress by advancing our pipeline and launching the world’s first Omicron BA.4/BA.5 adapted bivalent COVID-19 vaccine. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Next-generation antibody in our oncology pipeline: we have signed an exclusive worldwide license and collaboration agreement with OncoC4 to co-develop and commercialize their anti-CTLA-4 monoclonal antibody candidate ONC-392. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Bye bye Europe, hello Africa! The containers for our 1st BioNTainer just arrived in Kigali after a bit more than 24 hours of traveling by truck and plane. Thank you to H.E. President @PaulKagame, his ministers and teams as well as honorable guests. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We signed a Memorandum of Understanding with the @WeizmannScience in Israel to jointly conduct basic and applied #research with the aim to better understand various diseases, including cancer, infectious diseases, and neurodegenerative diseases. More: investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We are saddened by the loss of many lives in Türkiye and Syria. The humanitarian situation across Ukraine also remains dire. We are thankful for the first responders and will donate €500,000 each to Aktionsbündnis Katastrophenhilfe and @unoflucht. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We are strengthening our manufacturing capabilities in Marburg, Germany, with a EUR 40m investment: We have finished construction of our first in-house plasmid DNA manufacturing facility. German Chancellor @Bundeskanzler @OlafScholz visited the site today. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE reposted
Rwanda Food and Drugs Authority
@RwandaFDA
This Morning, a delegation from @BioNTech_Group paid a courtesy visit to the @RwandaFDA team.
Both parties discussed on the upcoming shipment of BionTrainers expected in Kigali soon. -
BioNTech SE
@BioNTech_Group
We aim to strengthen the “tech” in BioNTech with our agreement to acquire @instadeepai to support our strategy to build world leading capabilities in #ai- and #ml-driven #drugdiscovery and development of next-generation immunotherapies and vaccines. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We today announced signing an MoU with the UK government to accelerate trials for personalized #mrna #immunotherapies. Our objective: providing personalized cancer therapies for up to 10k patients by end 2030 in clinical trials or as authorized treatments. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We and our partner Fosun Pharma are happy that the mRNA-based #covid19 vaccine doses we provided for German expatriates in #china have arrived in Beijing! We thank the Chinese and the German governments for their joint efforts and continuous support. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
mRNA approach to target malaria: Today, we announced the initiation of a first-in-human Phase 1 study with BNT165b1, the first candidate from our BNT165 program for the development of a multi-antigen malaria vaccine candidate. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
The six containers comprising our #biontainer for our first planned manufacturing facility in Africa were produced in Europe, underwent quality checks and are being prepared for shipment to Kigali, Rwanda, where they are expected to arrive in Q1 2023. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Today, we have announced that the first subject was dosed in a first-in-human Phase 1 clinical trial with BNT163, a prophylactic herpes simplex virus 2 vaccine candidate. The program is part of our collaboration with the @Penn. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Driven by scientific rigor & deeply rooted in academia, passing on our knowledge is part of our legacy. We've started an intl. PhD program with @tronmainz, focusing on translational medicine. Interested? The application deadline is January 15th, 2023. jobs.biontech.com/job/Mainz-ATLAS-PhD-Program-RP-55131/87…
-
BioNTech SE
@BioNTech_Group
Together with @Pfizer we received the U.S. @US_FDA Fast Track Designation for our mRNA-based combination vaccine candidate for #influenza and #covid19, which aims to help prevent two respiratory diseases with a single injection. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We’ve celebrated the festive season with a digital winter show. It was what we are all about: collaborating, having fun & loving science. While a few colleagues engaged in game show formats in a studio, others received a game box at home & were able to participate live.
-
BioNTech SE
@BioNTech_Group
Today, the U.S. @FDA granted Emergency Use Authorization (EUA) of @Pfizer’s and our Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children 6 months through 4 years of age. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We announced today with @Pfizer the submission of an application to the @US_FDA for the emergency use authorization (EUA) of the Omicron BA.4/BA.5-adapted bivalent #covid19 vaccine for children 6 months through 4 years of age. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Today we announced a new multi-target research collaboration with @RyvuTx for multiple small molecule #immunotherapy programs aimed at immune modulation in cancer and potentially other disease areas. Read more: investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We published new data on the immune response induced by our Omicron BA.4/BA.5-adapted bivalent #covid19 vaccine against newer Omicron sublineages, incl. BA.4.6, BA.2.75.2, BQ.1.1 & XBB.1. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We and @pfizer started a Phase 1 trial for #bnt162b4 aimed at enhancing the breadth of t cell responses. This is part of our next generation #covid19 vaccine candidate approach. Goal: potentially broaden and extend the duration of protection against COVID-19.
-
BioNTech SE
@BioNTech_Group
Excited to getting one step closer to expanding our global footprint to Asia by acquiring a GMP manufacturing site to establish our first #mrna facility in #singapore. The site is expected to be operational in late 2023 and to create more than 100 jobs. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
A booster dose of our Omicron BA.4/BA.5-adapted bivalent #covid19 vaccine developed with @Pfizer has been recommended for marketing authorization by the @EMA_News’ #chmp for children 5-11. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Q3 results published: We reported pipeline expansion as well as first-to-market Omicron BA.4/BA.5 adapted bivalent #covid19 vaccine. Q3 revenues were at ~€3.4 bn (9M: €13 bn); raised FY 2022 guidance to upper end of the range to €16-17 bn. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We announced today with @Pfizer updated 30-day data for the 30-µg booster dose of our Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Together with our partner @pfizer, we today announced the start of a Phase 1 clinical study in the U.S. for a single dose #mrna-based combination vaccine candidate for seasonal influenza and COVID-19. The first patient has already been dosed. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
If you want to learn more about BioNTech's vision, here is a great BBC piece. @bbclaurak, we hope we will continue the talk soon!
BBC Politics
@BBCPolitics
"Changing cancer patients' lives is in our grasp"
BioNTech co-founders tell #bbclaurak how the same technology used to develop Covid vaccines could help fight cancer
Watch the full interview tomorrow on @BBCOne at 09:00 www.bbc.co.uk/news/health-63247997 -
BioNTech SE
@BioNTech_Group
We announced with @Pfizer early data from a Phase 2/3 clinical trial evaluating the safety, tolerability, and immunogenicity of our Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
.@US_FDA has granted an Emergency Use Authorization for a 10-µg booster dose of our Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 5-11 years of age. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We agreed to a letter of intent with the Australian State of Victoria. The partnership aims to accelerate drug development from discovery to development and delivery. More: investors.biontech.de/news-releases/news-release-details/…
10 News Melbourne
@10NewsMelb
Melbourne will soon lead the world in ground-breaking cancer research and treatment, with the city selected as BioNTech's second home for a medical hub that will host clinical trials as well as manufacturing | @brendancrew #springst
This media couldn't be displayed. See it on the original post. -
BioNTech SE
@BioNTech_Group
We and our partner @pfizer completed the regulatory submission for our #omicron BA.4/BA.5-adapted bivalent #covid19vaccine for children 5-11 years of age to @EMA_News - only a few days after the submission to @US_FDA.
-
BioNTech SE
@BioNTech_Group
We completed, together with @Pfizer, the submission to the @US_FDA requesting Emergency Use Authorization (EUA) of a 10-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children aged 5-11. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
The CHMP of the @EMA_news recommended converting the conditional Marketing Authorization for our COVID-19 vaccine to a full Marketing Authorization. The CHMP also recommended approval for our COVID-19 vaccine as a 10-µg booster dose for children aged 5-11. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Today we received the conditional marketing recommendation for our Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine by the Committee for Medicinal Products for Human Use (#chmp) of @EMA_News as a booster for individuals 12 years or older investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
BNT211 update at @myESMO: we shared positive follow-up data from our first-in-human Ph. 1/2 trial of our novel CAR-T cell therapy candidate. The data demonstrates encouraging signs of clinical anti-tumor activity & manageable safety & tolerability profile. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
A commitment to global public health: Ugur Sahin met with Israel’s Minister of Economy & Industry @OrnaBarbivay, Accountant General @RothenbergYali and other officials to discuss a potential collaboration with Israel and its academic institutions. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
+++Omicron BA.1-adapted bivalent vaccine update+++ Our BA.1 Bivalent COVID-19 Vaccine was recommended for conditional marketing authorization by @EMA_News' Committee for Medicinal Products for Human Use as a booster dose for individuals 12 years and older. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
+++ Omicron BA.4/BA.5 vaccine update +++ The FDA today granted Emergency Use Authorization (EUA) of a 30-µg booster dose of our Omicron BA.4/BA.5 bivalent vaccine, as a booster for individuals ages 12 years and older. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We completed with the submission for an Omicron BA.4/BA.5-adapted bivalent vaccine to the @EMA_News (#ema) together with our Partner @pfizer and are ready to ship as early as September, if regulatory approval is granted. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We have published updated #covid19 vaccine data supporting efficacy and safety in children from 6 months through 4 years of age. The updated analysis showed 73.2% vaccine efficacy and a favorable safety profile. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
In order to address the continued evolution of the SARS-CoV-2 variants, we have submitted an application for our Omicron BA.4/BA.5-adapted bivalent #covid19 vaccine to the @US_FDA. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Q2 results published: We reported strong advances in pipeline expansion and corporate development, with quarterly revenues of €3.2 bn (H1: €9.6 bn), reiterating our guidance for FY 2022 based on signed orders of 2.5 bn doses in 2022. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We expand our collaboration with @Genmab in cancer immunotherapy towards monospecific #antibodies, with the candidate BNT313 expected to enter clinical trials by end of 2022. We will share costs & potential profits on a 50:50 basis. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Proud of #teambiontech!
Boris Johnson
@BorisJohnson
Today I met the founders of @BioNTech_Group and thanked them on behalf of the country for their critically important work in fighting the pandemic.
Together, we can build on the success & collaboration of our Covid vaccine programme to tackle other big public health challenges. -
BioNTech SE
@BioNTech_Group
We and @pfizer started a Phase 2 trial for our next-generation #covid19 vaccine candidate #bnt162b5 based on an enhanced spike protein. Aim: Increased magnitude & breadth of immune response to improve protection from COVID-19. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We have reached a new supply agreement with the U.S. government for 105 million #covid19 vaccine doses (30, 10 & 3µg). This may include adult Omicron-adapted COVID-19 vaccines, subject to authorization from @US_FDA. First doses are planned to be delivered as soon as late summer.
BioNTech SE
@BioNTech_Group
Link to press release: investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We announced positive data on the safety, tolerability & immunogenicity of 2 Omicron-adapted vaccine candidates (mono- & bivalent). Preliminary lab studies showed both candidates neutralizing Omicron BA.4 and BA.5 though to a lesser extent than for BA.1. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE reposted
Presidency | Rwanda
@UrugwiroVillage
President Kagame breaks ground at the Kigali Special Economic Zone for BioNTech Vaccine Manufacturing Facility, attends the CBF roundtable, the Kigali Summit on Malaria and Neglected Tropical Diseases (NTDs), and hosts heads of state and government attending #chogm2022
This media couldn't be displayed. See it on the original post. -
BioNTech SE
@BioNTech_Group
We’re honored to have welcomed our African partners for the first time on the African continent as construction began for the initial African #mrna manufacturing facility in Kigali, Rwanda, 4 months after we introduced the #biontainer concept in February. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
The @EMA_News just granted PRIME designation to our CAR-T cell candidate BNT211 for the third line treatment of testicular cancer. This will accelerate the assessment of BNT211 and underlines the potential of our approach in the high medical need setting. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Preliminary Ph1 data from our and @Genentech’s individualized #mrna based cancer vaccine program (BNT122 in our pipeline) presented at #asco22. The data in patients with pancreatic cancer showed a favorable safety profile & was highly immunogenic in 8/16. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We concluded our AGM '22 with all resolutions passed by our shareholders. Helmut Jeggle was reappointed as Chairman of the SB, with two new members joining. Shareholders passed the proposal to pay a special cash dividend of €2 per ordinary share. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We published data indicating that a low dose of 3 µg of our #mrna COVID-19 vaccine, carefully selected based on tolerability data, is effective and provides children under 5 years of age with a high level of protection against the recent #covid19 strains. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Today, we presented our Q1 results. We demonstrated continued execution across our growth pillars in addressing infectious diseases and oncology and have invoiced more than 750 million doses of our COVID-19 vaccine in Q1 2022. More here: investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
For a medicine of tomorrow: This is the guiding theme of our Annual Report, which we have published today. We look back at an exceptional year and share details on our company and, importantly, on our science. Read more: investors.biontech.de/static-files/63dfd984-c1ce-46df-b54…
-
BioNTech SE
@BioNTech_Group
Preliminary Ph1/2 data from our first-in-class CAR-T program BNT211 at #aacr22 presented! BNT211 is the first CAR-T cell therapy candidate to treat solid tumors – if successfully developed, this could mean a medical breakthrough in #cancer therapy. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We are one of the companies in Germany to be granted a #pandemicpreparedness contract by @BMG_Bund. The framework agreement is aimed at pandemic preparedness including manufacturing & supply of #mrna vaccines in emergency situations in Germany. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We are pleased to have had H.E. @PaulKagame visiting our #biontech headquarters in Mainz. It was an honor to provide an impression of our cutting-edge technologies and scientific work happening in our labs every day. We share the goal of bringing novel medicines to #africa.
Paul Kagame
@PaulKagame
I had the great opportunity to visit with Uğur Şahin at @BioNTech_Group facility in Mainz, Germany. Impressive innovations in biotech! #highlevelstuff. A very good person and couple he and Dr. Özlem Türeci are!
-
BioNTech SE
@BioNTech_Group
Today, we presented our full year results. 2021 was a year of momentous impact that we have made on human health and the global economy, but also with regards to the transformation of #biontech. More here: investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
BioNTech SE supports humanitarian aid for the people of Ukraine with a donation of one million Euro to the nonprofit organization for refugee relief ‘UNO-Flüchtlingshilfe’ – the partner of UN Refugee Agency (UNHCR) in Germany. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Our COO Sierk Poetting is an expert in manufacturing, automation & digitalization. He has now been appointed Chairman of the Board at @meetIQM, a quantum computing company where he will contribute his expertise in these areas. Congratulations, Sierk! www.meetiqm.com/articles/press-releases/new-iqm-chairman/
-
BioNTech SE
@BioNTech_Group
Boosting our #celltherapy portfolio: we announced a collaboration with @MedigeneAG to develop T cell receptor immunotherapies against cancer, aiming at new treatments which address solid tumors with high unmet medical need. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE reposted
Tedros Adhanom Ghebreyesus
@DrTedros
This project, in conjunction with the mRNA vaccine tech transfer hub in South Africa, will provide Africa with needed and sustainable production capacities. I wish BioNTech every success in this endeavour, and I am confident that together, we can be successful. #vaccinequity
-
BioNTech SE reposted
Ibrahim Mayaki
@NEPAD_Mayaki
Honored to be with African leaders @PaulKagame @Macky_Sall @DrTedros who deliver milestones on our pathway to vaccine security. The partnership of @BioNTech is valued as it is writing the story of the new biopharma industry in the continent #theafricawewant
Tedros Adhanom Ghebreyesus
@DrTedros
Glad to talk to my brothers, #senegal President @Macky_Sall and #rwanda President @PaulKagame, CEO @NEPAD_Mayaki #nepad about the way forward on #vaccinequity in Africa. I thanked them for their steadfast leadership on the #covid19 pandemic response.
-
BioNTech SE reposted
Tedros Adhanom Ghebreyesus
@DrTedros
Pleased to join the #vaccinequity for Africa event in Marburg 🇩🇪 along side Presidents of 🇸🇳 @Macky_Sall, 🇬🇭 @NAkufoAddo, 🇷🇼 @PaulKagame, 🇪🇺 @vonderleyen, 🇩🇪 Chancellor @OlafScholz, @_AfricanUnion Chair @AUC_MoussaFaki to launch the BioNContainer mRNA vaccine initiative.
-
BioNTech SE
@BioNTech_Group
At a high-level meeting in Marburg we introduced a turnkey #mrna manufacturing solution called #biontainer for scalable vaccine production in Africa. We are working with our country partners& @WHO, @AfricaCDC, AMA and @EU_Commission to establish end-to-end manufacturing network
-
BioNTech SE
@BioNTech_Group
We initiated a rolling submission for an amendment to the #eua of our #covid19 vaccine to incl. in children 6mths - <5yrs following a request from the #fda. We plan to share these data with the #ema and other regulatory authorities. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
2021 was a year of historic impact that #biontech has had on global health. We expect 2022 to be a year of tremendous expansion and a once in a generation opportunity to transform medicine. Our aim: to harness the power of the immune system to fight human diseases.
-
BioNTech SE
@BioNTech_Group
We, together with @instadeepai, have developed an Early Warning System as a new computational method detecting high risk #sars-CoV-2 variants. In trial period, the system identified >90% of @WHO designated variants 2mths before their official designation. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Next generation #immunotherapy: we announced a collaboration with @HUMABODY. The aim is to develop precision immunotherapies, multi-specific mRNA-based antibodies & engineered cell therapies, to deliver breakthrough precision medicines for patients. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We announced a global collaboration with @Pfizer to develop the first #mrna-based Shingles vaccine, a disease affecting one in three people in the U.S. during their lifetime. Clinical trials are expected to start in H2/2022. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We celebrated #teambiontech at our virtual Christmas party. Our colleagues received a meal kit to cook dinner with at home while watching a few colleagues who cooked live in a studio. Thank you to Özlem, Sierk, Jens and Ryan who were rockin’ around the pots and pans!
-
BioNTech SE
@BioNTech_Group
Our colleague, Özlem Türeci, who is deeply rooted in science, accepted a professorship for “Personalized Immunotherapy” at @uni_mainz_eng Medical Center and the Helmholtz Institute for Translational Oncology (HI-TRON Mainz). Congratulations, Özlem!
-
BioNTech SE
@BioNTech_Group
The celebration of the topping-out of our new #inest manufacturing facility in Mainz, Germany, with special guest Malu #dreyer, Minister President of Rhineland-Palatine, was an important milestone on our way to turning our vision of individualized cancer medicine into a reality.
-
BioNTech SE
@BioNTech_Group
Based on our knowledge about the mechanisms behind the #covid19 vaccine & the biology of tested variants, we believe immunized people would have a high level of protection against severe disease even if infected by Omicron, writes @bopanc about his talk with Ugur Sahin in @WSJ.
Bojan Pancevski
@bopanc
Don’t panic: The Omicron variant could lead to more infections among vaccinated people but they will most likely remain protected from a severe course of illness, according to the @BioNTech_Group co-founder www.wsj.com/articles/omicron-unlikely-to-cause-severe-ill…
-
BioNTech SE
@BioNTech_Group
Together with the @deutschesmuseum, we revealed a brand-new exhibition piece: The bioreactor we used to produce the first dose ever of our #covid19 vaccine. We are honored to have a piece of us be presented alongside notable other objects that have been pivotal to human welfare.
-
BioNTech SE
@BioNTech_Group
The @EMA_News' CHMP issued a positive opinion on the administration of our #covid19 vaccine in children 5 to under 12 years of age. If approved, our COVID-19 vaccine will be the first to be authorized in the European Union in this age group. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
First & only disclosed longer-term data demonstrating the safety & efficacy of a COVID-19 vaccine in individuals 12-15 yrs: Findings show that our #mrna vaccine was 100% effective against #covid19, measured 7 days through over 4 months after the 2nd dose. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
The @US_FDA has granted Fast Track Designation for our investigational cancer immunotherapy BNT111. This underlines the potential of our #fixvac platform to address treatment challenges in patients with #melanoma and will expedite BNT111’s development. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Our collaborator @zipline completed the 1st long-range drone delivery of our #covid19 vaccine in Ghana. This underlines our shared focus to pioneer solutions to address COVID-19 vaccine access challenges in low & lower-middle income countries. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We had a strong Q3 with regards to our #covid19 vaccine distribution & oncology pipeline advancement. We supplied 149 countries & territories with over 2bn doses & expanded access to add. age groups. At the #sitc21, we'll report positive clinical data for 7 oncology programs.
-
BioNTech SE
@BioNTech_Group
Our Co-founders Ugur Sahin and Özlem Türeci talked to @TheAtlantic journalist @DKThomp about the potential of #mrna and the new era of medicine it could bring about. www.theatlantic.com/ideas/archive/2021/10/mrna-vaccines-c…
-
BioNTech SE
@BioNTech_Group
95.6% relative vaccine efficacy against #covid19 after a booster shot with our #mrna vaccine, during a period when Delta was the prevalent strain. These are the first efficacy results from any randomized, controlled vaccine booster trial. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
The #ema’s CHMP issued a positive opinion for a new formulation of our #covid19 vaccine which is already diluted and, therefore, enables simplified handling of the vaccine. It also allows for longer storage. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We've submitted data supporting the vaccination of children 5 to <12 yrs of age with our #covid19 vaccine to the @EMA_News for a variation of the Conditional Marketing Authorization. The same data have been submitted to the @US_FDA & others.
investors.biontech.de/press-releases -
BioNTech SE
@BioNTech_Group
We look forward to giving an update on our #oncology portfolio @sitcancer 36th Annual Meeting sharing data from multiple drug classes along with first-in-human data for three programs. #sitc21 More here: investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We're continuously expanding our later-staged clinical oncology pipeline: today, we announced the that the first patient has been dosed with a candidate from #biontech’s #mrna-based cancer vaccine platform in a Phase 2 trial. For more on the approach:
investors.biontech.de/static-files/8701f4f0-fdca-44e7-a31… -
BioNTech SE reposted
TechCrunch
@TechCrunch
BioNTech's mission is to make treatments that are optimized not only to specific patient needs, but also to time and place. All the treatments in @BioNTech_Group's pipeline are about refining society's approach to addressing diseases.
-
BioNTech SE reposted
Paul-Ehrlich-Stiftung
@PaulStiftung
Für ihre Erforschung und Entwicklung von messenger-RNA (mRNA) zu präventiven und therapeutischen Zwecken werden Katalin Karikó, Özlem Türeci und Uğur Şahin mit dem Paul Ehrlich- und Ludwig Darmstaedter-Preis 2022 ausgezeichnet. >>> tinygu.de/peldp22
-
BioNTech SE
@BioNTech_Group
Results from our Phase 2/3 in children 5-11yrs of age showed a favorable safety profile & robust neutralizing antibody responses, using a 2 dose regimen of 10 µg. We plan to share the data with the @US_FDA, @EMA_News & other regulators. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Science or Art? A new publication about the potential of mRNA as therapeutic option for cancer in @AAAS. The clinical trial is ongoing. www.science.org/toc/stm/13/610
-
BioNTech SE
@BioNTech_Group
Invited by the @KenupFoundation, President @PaulKagame of Rwanda, President @Macky_Sall of Senegal, & @EU_Commission President @vonderleyen met #biontech CEO Uğur Şahin to discuss the establishment of vaccine manufacturing capabilities in the AU. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We announced the signing of a letter of intent with Brazilian biopharmaceutical company Eurofarma Laboratórios to manufacture our #covid-19 vaccine for distribution within Latin America. This is an important step to broaden the access to vaccines. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
The @US_FDA approved the Biologics License Application for our #mrna vaccine to prevent #covid19 in individuals 16yrs & older. #biontech is the Marketing Authorization Holder in the U.S., making it the 1st COVID-19 vaccine granted approval by the FDA. edition.cnn.com/2021/08/23/health/fda-approval-pfizer-cov…
-
BioNTech SE
@BioNTech_Group
We want to make a difference for individuals and humankind. Our strategy remains focused on bringing our broad pipeline of Next-Generation Immunotherapies and #vaccines to people worldwide to address #cancer and a growing list of infectious diseases: investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Welcoming >50 new colleagues in Gaithersburg, MD! The 3rd acquisition in 14 months confirms our strategy of complementing organic growth through targeted acquisitions that expand our capabilities & accelerate the development of our immunotherapy pipeline.
-
BioNTech SE
@BioNTech_Group
“mRNA could be the next revolution in the biopharmaceutical landscape” said one of our co-founders Ugur Sahin and Özlem Türeci who joined @TEDChris for a #tedmonterey talk about #covid19. Learn more about our #mrna technology and what’s next. www.ted.com/talks/ugur_sahin_and_ozlem_tureci_meet_the_sc…
-
BioNTech SE
@BioNTech_Group
We want to help eradicate Malaria. Therefore, we’re launching a project aimed and developing a well-tolerated and highly effective Malaria vaccine and implement sustainable vaccine supply solutions on the African continent.
investors.biontech.de/news-releases/news-release-details/… -
BioNTech SE
@BioNTech_Group
The recent flood disaster in Germany has a dramatic effect on a large number of people who've lost relatives, friends and homes. In solidarity, we will be donating 1 million € to the German Alliance for Disaster Relief (Aktionsbündnis Katastrophenhilfe). investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Our first manufacturing partner within the African Union has just been announced! @biovac_inst is a Cape Town based biopharmaceutical company which will support the production of more than 100m doses of our #covid19 vaccine as well as the distribution.
investors.biontech.de/news-releases/news-release-details/… -
BioNTech SE
@BioNTech_Group
We want to help to bring this pandemic to an end. In light of the #deltavariant, we have early added a new pillar to our comprehensive #covid19 booster strategy – keeping us ahead of the COVID-19 virus. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Vielen Dank an alle Referent:innen und Teilnehmer:innen des 1. mRNA-Kongresses von BioNTech. Ihre große Begeisterung für das Thema und die Diskussionen zeigen, dass wir gemeinsam auf dem richtigen Weg sind: aus der Pandemie zurück in ein normales Leben.
-
BioNTech SE
@BioNTech_Group
We want to revolutionize cancer treatment and we continue to advance our pipeline: the first patient has been treated in our BNT111 randomized Phase 2 trial. BNT111 is the lead product candidate from our proprietary FixVac platform. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We've reached a new milestone: We've manufactured 1bn doses of our #mrna based #covid19 vaccine together with our partner @Pfizer. Our teams go above & beyond every day to bring the vaccine to as many people as possible around the world. Kudos to our colleagues! #teambiontech
-
BioNTech SE
@BioNTech_Group
Exzellenter Auftakt für den #mrna-Kongress am 12. Juni: Die Eröffnungskeynote hält Dr. Özlem Türeci Mitgründerin und CMO von #biontech. Jetzt anmelden unter: event.biontech.de/nocode.
Die Teilnahme ist #kostenfrei für alle. -
BioNTech SE
@BioNTech_Group
Addressing a pandemic requires global collaboration. As part of our pledge of 2bn doses to broaden access to our #covid12 vaccine, we’re providing 500m doses at a not-for profit price to the US for donation to ≈100 low- & lower middle-income countries. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
The @EU_Commission expanded the conditional marketing authorization for our #covid19 vaccine to incl. individuals 12-15rys of age. Our pediatric studies evaluating the safety & efficacy of our vaccine in children from the ages of 6mths - 11yrs are ongoing. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE reposted
Ursula von der Leyen
@vonderleyen
We are working closely with our industrial partners to supply vaccines to low & middle income countries.
They just pledged to make available 1.3 billion doses to these countries in 2021.
1 billion from @BioNTech_Group @Pfizer
200 million from @JNJNews
100m from @Moderna_tx -
BioNTech SE
@BioNTech_Group
We have published our first Sustainability Report. The publication is a milestone for us, showcasing not only the contribution we aspire to make to society through our innovative research, but also the wider responsibility we take on as a company. investors.biontech.de/static-files/7b130edf-10ca-47d7-aa2…
-
BioNTech SE reposted
Ursula von der Leyen
@vonderleyen
Our new 🇪🇺 contract 2021-2023 with @BioNTech_Group @Pfizer is now signed.
It guarantees up to 1.8 billion doses for our fight against COVID and its variants.
Contracts with other companies may follow, to protect Europe and the world in the long term.
europa.eu/!cq33kC -
BioNTech SE
@BioNTech_Group
We plan to supply the EU with up to 1.8b additional doses of our #covid19 vaccine & entered a new agreement with the @EU_Commission to supply 900m doses of our COVID-19 vaccine to the EU, with an option to request up to an additional 900m doses. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Welcoming Jens Holstein to our team as of Jul. 1 as our new CFO. Dr. Sierk Poetting will hand over the CFO role to Jens to completely focus on his tasks as COO. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
.@EMA_News has approved a change to the existing storage conditions for our #covid19 vaccine: The thawed, undiluted vaccine can be stored at fridge temperatures of 2-8°C for 1 month, instead of 5 days at fridge temperatures, as previously indicated. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
The #fda has expanded the EUA for our #mrna based #covid19 vaccine to include adolescents 12-15 yrs. This is an important milestone in our efforts to help address the global pandemic and to return to normalcy. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Q1 updates: we delivered > 450m doses of our COVID-19 vaccine globally. We’ll further optimize our technologies and expand our pipeline as we meet our ambition to become a global, fully-integrated immunotherapy company. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We’re excited to announce our plans to establish our first regional hub in #asiapacific region & 1st #mrna manufacturing facility in #singapore – expanding our ability to manufacture & deliver #mrna vaccines & potential therapies to people around the world investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
#tokyo2020 オリンピック・パラリンピック競技大会の参加選手と代表団に、新型コロナウイルスのワクチンを無償提供することを誇りに思います。このような特別なイベントへの支援機会を提供してくれた @iocmedia に感謝します。investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We are proud to provide doses of our #covid19 vaccine to help vaccinate athletes & delegations in the Olympic & Paralympic Games #tokyo2020. We thank the @iocmedia for the opportunity to support this extraordinary event in these times. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Curious about the future of #health? Our Chief Medical Officer, Özlem Türeci, shared our vision for the potential of #mrna technology at the #aspenideashealth event. Thank you @AspenIdeas for providing such an important platform.
youtu.be/NQAEaibWUpw -
BioNTech SE
@BioNTech_Group
We’ve just submitted a request for a variation of our Conditional Marketing Authorization to @EMA_News for our #mrna #covid19 vaccine to be extended to adolescents 12-15 yrs. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We’re excited to be in @TIME’s first 100 Most Influential Companies list. This honors the hard work of our #teambiontech & @Pfizer colleagues, who went above & beyond to develop & manufacture our #mrna COVID-19 vaccine in light speed. #time100companies time.com/collection/time100-companies/5953642/pfizer-bion…
-
BioNTech SE reposted
Ursula von der Leyen
@vonderleyen
Ich bin froh, heute den @Pfizer Standort in Purrs zu besuchen.
Die Impfungen in der EU schreiten dank verlässlichen Partnern wie @Pfizer & @BioNTech_Group zügig voran.
So können wir bereits bis zum Juli 70 Prozent aller Erwachsenen ein Impfangebot machen. -
BioNTech SE
@BioNTech_Group
We welcomed @TIME to our site in Marburg for a unique behind-the-scenes look at all steps involved in manufacturing our #mrna based #covid19 vaccine. We are so proud of our #teambiontech whose hard work has contributed to a global solution. The video shows some of our heroes.
TIME
@TIME
Inside the facilities making the world's most prevalent COVID-19 vaccine ti.me/3gp8tfa
This media couldn't be displayed. See it on the original post. -
BioNTech SE
@BioNTech_Group
“What we have seen in the COVID-19 field is just the beginning” said Ugur Sahin in regards to mRNA at this year’s Virtual Health Summit by @Wired.
Watch the whole talk here: www.youtube.com/watch?v=KjDsTvTDddA. -
BioNTech SE
@BioNTech_Group
This week, the first vaccines manufactured in Marburg will be distributed to various European countries! What does one of the largest COVID-19 production facilities in Europe look like? Here is “where the magic happens” www.ft.com/content/cf5d6113-3698-4cc7-9d5b-8f0f29fd6a35
-
BioNTech SE
@BioNTech_Group
Our #covid19 vaccine is 91.3% efficacious 7 days through up to 6 months after the 2nd dose. Results are based on 46,307 trial participants (>12k received the vaccine 6 months ago) demonstrating strong protection.
Bojan Pancevski
@bopanc
The @Pfizer-@BioNTech_Group vaccine protects against symptomatic Covid-19 for at least six months and is highly effective against the South African variant, according to new findings released by the companies www.wsj.com/articles/pfizer-biontech-covid-19-vaccine-pro… via @WSJ
-
BioNTech SE
@BioNTech_Group
2020 has transformed #biontech. Our #covid19 vaccine has been approved or authorized in more than 65 countries and regions, with >200m doses supplied. What’s planned for this year? investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
The first batches of #mrna vaccines manufactured at Marburg are expected to be delivered in the second half of April. The @EMA_News has approved the commercial use of drug substance and drug product manufactured at the site. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Congratulations to Ugur Sahin & Özlem Türeci for having been awarded the Order of Merit of the Federal Republic of Germany by President Frank-Walter Steinmeier & Chancellor Angela Merkel. The award shows the difference that innovation and science can make. www.bundespraesident.de/error_path/400.html?al_req_id=avE…
-
BioNTech SE reposted
Axel Springer SE
@axelspringer
„Es gibt keine besseren Preisträger“ – BioNTech-Gründer Özlem Türeci und Uğur Şahin mit Axel Springer Award ausgezeichnet go2.as/3sdRcIA
-
BioNTech SE
@BioNTech_Group
A year ago, the @WHO declared the pandemic. Today, new real world data from Israel that give us further hope, indicate a high effectiveness of our vaccine in preventing symptomatic #covid19 and hospitalizations as well as asymptomatic infection (94%). investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Today, we especially celebrate all of our female co-workers: With over 54% female colleagues and 45% women in leadership roles, we’re proud to challenge the status quo in which women are still a minority in #science and #leadership positions! biontech.de #iwd2021
-
BioNTech SE reposted
Arab News
@arabnews
#franklyspeaking: The next challenge for the #covid19 vaccine inventor Dr. Ugur Sahin, Founder and CEO of @biontech_group, is to find a cure for cancer | Full episode: youtu.be/2q8qR3i2u0I
-
BioNTech SE
@BioNTech_Group
Our vaccine arrived in Rwanda, Africa - marking another important milestone in our efforts to make our #mrna #covid19 vaccine available across the globe. In partnership with @UNICEF, it will be used to vaccinate at-risk front-line healthcare workers. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We are pleased to announce that the first batch of our #mrna #covid19 vaccine arrived in Hong Kong last Friday and will be supplied to Hong Kong and Macao. This is another important milestone in our efforts to help address the global pandemic.
-
BioNTech SE reposted
WELT
@welt
Biontech-Gründer Özlem Türeci und Uğur Şahin bekommen Bundesverdienstkreuz www.welt.de/politik/deutschland/article227170241/Bundesve…
-
BioNTech SE
@BioNTech_Group
Creating the foundation today to address challenges of tomorrow: we’re evaluating a 3rd dose of our #covid19 vaccine against current & new variants. We’re also discussing regulatory pathways similar to that of the flu vaccine to adapt vaccines if needed. www.wsj.com/articles/pfizer-and-biontech-studying-third-c…
-
BioNTech SE
@BioNTech_Group
Our manufacturing site in Marburg takes on a key role in our efforts to address the global pandemic: By the 1st half of 2021, we plan to produce 250 mio. doses of our #mrna COVID-19 vaccine. @FT took a closer look at the facility's historical tradition: www.ft.com/content/13d23af0-5f0c-4215-a017-39f6b145d0e8?a…
-
BioNTech SE
@BioNTech_Group
We began manufacturing #mrna at our site in Marburg: one mRNA batch is enough to produce approx. 8 mio doses. We will submit production data to EMA in the upcoming weeks for final validation of the Marburg site in order to start supply in April. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE reposted
Science Magazine
@ScienceMagazine
Using samples from 40 people who had received the BioNTech-Pfizer COVID-19 vaccine, Alexander Muik (@BioNTech_Group) et al. report that this sera neutralizes the “UK” #sarscov2 variant largely as well as it does the Wuhan reference strain. science.sciencemag.org/cgi/doi/10.1126/science.abg6105
-
BioNTech SE reposted
EU Medicines Agency
@EMA_News
Just published: The first safety update on a #covid19vaccine is now available. It concludes that safety data collected on Comirnaty so far is consistent with the known safety profile of the vaccine, and no new #sideeffects were identified.
Read more: www.ema.europa.eu/en/news/first-covid-19-vaccine-safety-u… -
BioNTech SE
@BioNTech_Group
Our researchers found that the sera of BNT162 trial participants inhibited pseudovirus bearing the UK strain SARS-CoV-2 spike in a neutralization range that is regarded as biologically equivalent to the unmutated SARS-CoV-2 spike. More in @FT’s article on.ft.com/3p4zXIa
-
BioNTech SE reposted
The Reis Group
@TheReisGroup
@MatthewHerper asked about the reaction upon learning their #covidvaccine was 95% effective: “It was a very emotional moment.” -Ozlem Tureci, @BioNTech_Group
-
BioNTech SE
@BioNTech_Group
We are honored that our co-founders Dr. Ugur Sahin and Dr. Özlem Türeci are featured on the cover of @TIME this week. The accompanying article provides an inside look at BioNTech, our peers, and the science behind the COVID-19 vaccines developed around the world.
TIME
@TIME
TIME's new global cover: Inside the vaccine revolution ti.me/3qdaNYj
-
BioNTech SE
@BioNTech_Group
All 27 EU Member States received their first batches of our #covid19 vaccine. The picture below shows a couple of them. What a great day!
-
BioNTech SE
@BioNTech_Group
The @EU_Commission granted Conditional Marketing Authorization for our #mrna #covid19 for all 27 member states. For us, this marks the end of an extraordinary year & gives hope that we may be able to return to some sense of normalcy in 2021. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE reposted
Ursula von der Leyen
@vonderleyen
Every day counts - we work at full speed to authorise #covid19 vaccines that are safe & effective.
I welcome @EMA_News bringing forward its meeting to discuss the @pfizer/BioNTech vaccine, before Christmas.
Likely that the first Europeans will be vaccinated before end 2020! -
BioNTech SE
@BioNTech_Group
Our #vaccine candidate #bnt162b2 has been authorized by the @US_FDA for emergency use in the U.S. We stand ready to distribute our vaccine following authorizations or approvals from other regulatory authorities around the globe.
-
BioNTech SE
@BioNTech_Group
How do #mrna vaccines work? The @nytimes offers an overview of the mode of action
www.nytimes.com/interactive/2020/health/pfizer-biontech-c… -
BioNTech SE reposted
Bojan Pancevski
@bopanc
The married couple Ugur Sahin and Özlem Türeci, founders of @BioNTech_Group, invented the first #covid19 vaccine to be authorized in the West. But their jab is a byproduct of 30 years of cancer research. My piece via @WSJ www.wsj.com/articles/how-a-couples-quest-to-cure-cancer-l…
-
BioNTech SE
@BioNTech_Group
Exciting news: We received the world’s first authorization of a #covid19 #vaccine, with @MHRA granting emergency use authorization in the UK. More regulatory decisions may come in 2020. More information: www.gov.uk/government/news/pfizer-biontech-covid-19-vacci…
-
BioNTech SE
@BioNTech_Group
We have submitted a formal Application for Conditional Marketing Authorization to @EMA_News for #mrna vaccine candidate #bnt162b2 against #covid19. It will be assessed according to #ema’s normal stringent standards for quality, safety and efficacy. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We’re excited to announce a new strategic collaboration: We'll be establishing an #ai Innovation #lab with @instadeepai to advance a portfolio of initiatives across drug discovery & design, protein engineering, manufacturing and supply chain optimization. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We are submitting our first request for an #eua in the U.S. for vaccine candidate #bnt162b2 against #covid19. We look forward to continuously providing data to various regulatory authorities as part of our rolling review process – including the @EMA_News. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We have reached the final #efficacy analysis mark, indicating a high rate of protection against #covid19 can be achieved very fast after the second 30µg dose. We will share further details with the @EMA_News, @US_FDA & other regulatory authorities. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE reposted
Meg Tirrell
@megtirrell
Pfizer & BioNTech final results on #covid19 vaccine phase 3: *95% effective*
170 cases in trial
-162 among placebo group
-8 on vaccine
10 severe cases
-9 on placebo
-1 on vaccine
94% efficacy for those 65+
Fatigue, headache after 2nd shot
Plan to submit to FDA within days -
BioNTech SE
@BioNTech_Group
To our #twitter community: Please note there are no personal accounts being run by our executives. We are already in contact with @Twitter and @TwitterSupport to delete all personal accounts related #ugursahin and #oezlemtuereci.
-
BioNTech SE
@BioNTech_Group
你好Nǐ hǎo from China! This week we participated in @ciieonline to showcase our #mrna technology and how we aim to leverage it for individualized cancer medicine and a potential COVID-19 vaccine. A big thank you to our partner @Fosun_Intl for having us!
-
BioNTech SE
@BioNTech_Group
We are excited to welcome the latest addition to the BioNTech family: our colleagues in Marburg. The tech transfer is currently being made and we plan to start the production of potential #covid19 vaccines in 2021. Welcome to #teambiontech!
-
BioNTech SE reposted
Bojan Pancevski
@bopanc
How a Little-known German Biotech Firm Founded by the Children of Turkish Immigrants Became a Leader in Global #coronavirus Vaccine Race. My report via @WSJ: www.wsj.com/articles/how-pfizer-partner-biontech-became-a…
-
BioNTech SE
@BioNTech_Group
We provided an update on the potential timelines for the #covid19 #vaccine candidate BNT162b2. We will seek approval only if the data provides a clear picture in three key areas: safety, efficacy, manufacturing quality. Read more in @WSJ by @bopanc. www.wsj.com/articles/pfizer-could-apply-for-emergency-use…
-
BioNTech SE reposted
Genmab
@Genmab
We’re excited to share updates from Genmab’s pipeline at the virtual #sitc2020, including first-in-human data on a bispecific #antibody in joint development with @BioNTech_Group. Read more: ir.genmab.com/news-releases/news-release-details/genmab-a…
-
BioNTech SE
@BioNTech_Group
Phase 1 data of our #covid19 #vaccine candidate BNT162b2 was published in the @NEJM. It shows that BNT162b2 induces similar responses in both younger & elderly people and provides insights into our lead candidate selection for the pivotal study. @pfizer www.nejm.org/doi/full/10.1056/NEJMoa2027906
-
BioNTech SE
@BioNTech_Group
On Oct 10 2019, we joined @Nasdaq as $BNTX. Since then, we not only established our US headquarters, raised more than $700m in capital & further developed our oncology pipeline. We're working around the clock to develop a potential #covid19 vaccine to address the global pandemic.
-
BioNTech SE
@BioNTech_Group
We initiated a rolling submission to @EMA_News for our #covid19 #vaccine candidate BNT162b2. #chmp will now start reviewing pre-clinical data, while BNT162b2 will remain subject to #ema’s diligent standards for quality, safety and efficacy. investors.biontech.de/news-releases/news-release-details/…
EU Medicines Agency
@EMA_News
📢 EMA's human medicines committee (#chmp) starts the #rollingreview of a 2nd #covid19vaccine:
👉www.ema.europa.eu/en/news/ema-starts-second-rolling-revie…
#covid19 #unitedagainstcorona -
BioNTech SE reposted
EuropaBio
@EuropaBio
Starting soon - How can we prepare for future pandemics? Join us for our next @biotechweek event now w/ @EPPGroup's @peterliese, @BioNTech_Group's Sean Marett & @EUScienceInnov's Maria Pilar Aguar Fernandez
You can still register here: www.europabio.org/events/pandemic-preparedness-beyond-cov… -
BioNTech SE
@BioNTech_Group
Today we announced the acquisition of a manufacturing facility in Marburg, Germany. The site, which should be fully operational in H1 2021, will have an annual production capacity of 750 million doses of our promising #covid19 BNT162b2 #vaccinecandidate investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We are delighted to welcome 14 new apprentices at @BioNTech who share our vision to individualize cancer medicine. Under Corona safety measures, this year’s apprenticeship beginning was rather unique - but we successfully gave all new colleagues a warm welcome!
-
BioNTech SE
@BioNTech_Group
We are excited to receive a grant of up to €375M from the German Federal Ministry of Education and Research to accelerate our #covid19 #vaccine program BNT162 and scale-up the manufacturing capacities. Find the full PR here: investors.biontech.de/news-releases/news-release-details/…
BMFTR
@bmftr_bund
BMin @AnjaKarliczek & BM @jensspahn @BMG_Bund sprachen heute vor der #bpk über den neuesten Stand der #covid19 Impfstoff-Forschung. "Mit unserer Förderung werden Produktionskapazitäten ausgeweitet", so die Ministerin.
Mehr hier 👉 www.bmbf.de/de/corona-das-ist-der-stand-bei-der-impfstoff…
© BMBF / BPK, ZDFThis media couldn't be displayed. See it on the original post. -
BioNTech SE
@BioNTech_Group
We announced that we have concluded exploratory talks with the @EU_Commission for a proposed supply of 200 million doses of #covid19 #vaccine candidate #bnt162 to #eu member states with an option to purchase additional 100 million doses. biontechse.gcs-web.com/news-releases/news-release-details…
-
BioNTech SE
@BioNTech_Group
Today and every day, we put #science first. We are committed to the safety & efficacy of #vaccines & testing potential vaccines for #covid19 in accordance with high ethical standards & sound scientific principles.
#westandwithscience. @Novavax, we encourage you to stand with us
Moderna
@moderna_tx
We are proud to participate in this pledge to uphold the integrity of the scientific process in the research and development of a #covid19 vaccine. #westandwithscience, and @BioNTech_Group, we invite you to stand with us.
-
BioNTech SE
@BioNTech_Group
We just shared new key data from our U.S. Phase 1 trial for our lead vaccine candidate against #covid19#BNT162b2. Our global Ph3 study in up to 30k participants is actively enrolling. Up to date, we have dosed more than 11,000 participants! investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Today, we provided an update on our corporate progress and reported financial results for Q2. We made significant progress toward our goal of advancing our #oncology programs and toward bringing a #covid19 vaccine to market as quickly as possible. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
“We are proud to be among the first international biopharmaceutical companies to initiate a clinical trial of a #covid19 #vaccine candidate in #china as part of our effort to make our vaccine available globally, if approved,” said our CEO Ugur Sahin. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We announced an agreement with #japan for 120m doses of our mRNA-based vaccine candidate. This is part of our commitment to address the global health crisis together with @Pfizer as we hope it may help in bringing the world together at the #tokyoolympics. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We announced the start of a global Phase 2/3 safety and efficacy study to evaluate a single nucleoside-modified messenger RNA (modRNA) candidate from our #bnt162 mRNA-based vaccine program conducted together with our partner @Pfizer. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We announced an agreement with the #uk for 30m doses of our mRNA-based vaccine candidate against #covid19. We currently expect to manufacture up to 100m doses by the end of 2020 & potentially more than 1.3bn doses by the end of 2021 together with @pfizer. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We are proud to have received Fast Track designation from the U.S. FDA for two of our four investigational vaccine candidates from the #bnt162 mRNA-based vaccine program. They are being developed to help protect against #covid19. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Today, we announced early positive data from the #us and as part of our global #covid19 development program in collaboration with @pfizer. Find the key facts in our press release: investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Wie gestaltet sich die Entwicklung nach einem #impfstoff gegen #covid19 in einem globalen Umfeld? BioNTechs Mitgründer und CEO Ugur Sahin hat im Montagsinterview der @SZ mit @edostertsz. www.sueddeutsche.de/wirtschaft/coronavirus-impfung-biotec…
-
BioNTech SE reposted
DIE ZEIT
@DIEZEIT
"Lichtgeschwindigkeit" haben sie ihr Projekt getauft: Die Welt vom Virus befreien. @ingomalcher hat für die neue ZEIT-Serie "Die Menschen von" das Team von @BioNTech_Group portraitiert. Können Sie hier lesen:
www.zeit.de/2020/24/biontech-pharmaindustrie-impfstoff-fo… -
BioNTech SE
@BioNTech_Group
We have made significant progress to date in 2020: We advanced our #oncology pipeline, closed the acquisition of Neon Therapeutics & signed value-adding partnerships. We have also initiated a global clinical development program for a #covid19 #vaccine. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
#bntx grows globally: welcome to our new team members in the #us! We announced today the closing of @neon_tx. Based in Cambridge, MA, the subsidiary will operate under the name of BioNTech US Inc. and serve as our #us headquarters. #welcometotheteam www.biontech.com/us/en/home.html
-
BioNTech SE
@BioNTech_Group
Listen in to @CNN's @fpleitgenCNN discussing the progress of our global #covid19 development program with our CEO Ugur Sahin. Thanks for having us! edition.cnn.com/videos/business/2020/05/06/germany-us-bio…
-
BioNTech SE
@BioNTech_Group
The first participants in the #us were dosed with #bnt162. With ongoing trials in #europe and Northern America, our global vaccine development program is currently the only one with a #vaccine candidate being tested in participants on two continents. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
What a special moment! The first participant was dosed with our #covid-19 vaccine candidate BNT162. Furthermore, the first cohort of 12 study participants in our Phase 1/2 trial has been successfully completed.
-
BioNTech SE
@BioNTech_Group
Wann hat unser CEO und Mitgründer Ugur Sahin intern das #covid-19 Impfstoffprogamm initiiert? Was genau hat ihn dazu veranlasst? Hören Sie, wie er diese und weitere Fragen mit Chefredakteur @MichaelBroecker im Podcast von @gaborsteingart diskutiert. www.gaborsteingart.com/podcast/https-dasmorningbriefing-p…
-
BioNTech SE
@BioNTech_Group
Today, the German regulatory authority, the @PEI_Germany, approved the Phase 1/2 clinical trial for our #vaccine program to prevent #covid19 infection. More about the milestone in our global development program in collaboration with @pfizer & Fosun Pharma: investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
We are excited to have announced additional details on our collaboration with @pfizer to rapidly advance multiple mRNA-based COVID-19 vaccine candidates into clinical testing and ramp-up production capacities. investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Today, we announced our full year 2019 financial results. Last year has been transformational for us. In 2020, we plan to continue building a 21st century company to develop pioneering therapeutics for #cancer & other diseases with an unmet patient need. www.biontech.com/int/en/home/about/vision-and-mission.html
-
BioNTech SE
@BioNTech_Group
It's important to ensure our patients in clinical trials continue to get treatment & to pursue the development of a #covid19 vaccine. This is why our R&D & manufacturing coworkers continue to work in our labs, while the majority of our colleagues work from home. #westayhomeforyou
-
BioNTech SE
@BioNTech_Group
If you ever wondered what it is like to work with Ugur Sahin on the development of a #covidー19 vaccine, the @FT provides insights. www.ft.com/content/36ddd384-6abf-11ea-a3c9-1fe6fedcca75
-
BioNTech SE reposted
Business Insider 🇩🇪
@BIDeutschland
Nach @CureVacAG hat nun auch die Mainzer Firma
@BioNTech_Group angekündigt, einen Impfstoff gegen das #coronavirus entwickeln zu wollen. Die Biotech-Firma im Porträt👇#nasdaq #covid2019de #corona
www.businessinsider.de/wirtschaft/mainzer-pharmafirma-bio… -
BioNTech SE
@BioNTech_Group
Watch our Chief Business and Chief Commercial Office Sean Marett discuss BioNTech’s vaccine program for the prevention of Covid-19 infection and our global development program on @CNBC. www.cnbc.com/video/2020/03/17/biontech-coronavirus-vaccin…
-
BioNTech SE
@BioNTech_Group
Today, we announced that we have agreed to a letter of intent regarding the co-development & distribution (excl. China) of a potential mRNA-based coronavirus vaccine aimed at preventing #covid19 infection with @pfizer. Read our Press Release: investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE reposted
FAZ Wirtschaft
@FAZ_Wirtschaft
Das Biotechunternehmen @BioNTech_Group kooperiert für eine Impfung jetzt mit dem #fosun-Konzern aus China. Bald sollen klinische Tests starten. Jetzt lesen mit #fplus! #covid19 www.faz.net/aktuell/wirtschaft/unternehmen/mainzer-untern…
-
BioNTech SE
@BioNTech_Group
We are developing a potential mRNA-based vaccine to induce immunity and prevent #covid19 infections. We initiated our global development program in response to the growing global health threat. Read our press release: investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Today, we especially celebrate our female co-workers striving to turn our vision of individualized #cancer medicine into reality. While women are still a minority in #science & #leadership positions, we are proud to set an example. #iwd2020 #eachforequal biontech.de
-
BioNTech SE
@BioNTech_Group
At @SVBLeerink’s Global Healthcare Conference, Sean Marett and Ryan Richardson discussed our vertically integrated approach build on in-house diagnostics, a multi-drug class approach, off-the-shelf drugs & individualized therapies & in-house manufacturing. biontech.de/our-dna/vision
-
BioNTech SE
@BioNTech_Group
2019 haben wir $225m mit einer Series B-Finanzierungsrunde & $149m mit einem @Nasdaq #ipo akquiriert. Laut @FAZ gehören wir zu den 3 deutschen Unternehmen, die im letzten Jahr so viel Wagniskapital eingesammelt haben, wie kaum ein Unternehmen in #europa. www.faz.net/aktuell/finanzen/finanzmarkt/wie-viel-investi…
-
BioNTech SE
@BioNTech_Group
By combining groundbreaking research with cutting-edge technologies, we are building a 21st century company in order to develop pioneering therapeutics for #cancer and other diseases with an unmet patient need. Learn more about our vision: biontech.de/our-dna/vision
-
BioNTech SE
@BioNTech_Group
We are excited to announce that we have entered into a definitive #merger #agreement under which we will acquire @neon_tx to strengthen our #global #leadership position in T #celltherapies. Read more here: investors.biontech.de/news-releases/news-release-details/… #immunooncology #cancerimmunotherapy #oncology
-
BioNTech SE
@BioNTech_Group
Yesterday our CBO & CCO Sean Marett discussed the future of cell & gene therapies at the #biotechshowcase highlighting the importance of manufacturing of #cell-based therapies.That is why we are in the process of further expanding our in-house capabilities in the next years $BNTX
-
BioNTech SE
@BioNTech_Group
We are excited to announce the #appointment of Ryan Richardson as Chief Strategy Officer and Managing Director. Ryan will support us in our long-term #growth #strategy to become a #leading #global #biotech company. Read the full PR here: investors.biontech.de/news-releases/news-release-details/…
-
BioNTech SE
@BioNTech_Group
Meet Sean Marett, our CBO & CCO at the #biotechshowcase on January 14, 2020, in San Francisco, where he will discuss the future of #cell & #gene #therapies on a panel at 8.00 am PT #cart #jpm20 informaconnect.com/biotech-showcase/agenda/3/
-
BioNTech SE
@BioNTech_Group
Interested in European biotech companies? We are happy to be named one of the 20 European #biotech companies to follow this year. @Labiotech_eu consulted with experts to identify the companies across all areas of biotech. #2020 Check out the entire list: www.labiotech.eu/tops/european-biotech-companies-2020/
-
BioNTech SE
@BioNTech_Group
Preclinical PoC data on our first solid #tumor #cart program BNT211 were published in the current issue of @sciencemagazine. Read the full paper on how we aim to overcome the existing hurdles and create an efficient approach with our CARVac technology here science.sciencemag.org/content/early/2019/12/30/science.a…
-
BioNTech SE
@BioNTech_Group
We announced a €50M financing from @EIB to advance R&D, market access and manufacturing development of our most advanced treatments under development. #junkerplan #europe #innovation
-
BioNTech SE
@BioNTech_Group
We are on top in @GENbio’s ranking of the 10 best immuno-oncology start-ups of 2019. Thanks @AlexWestchester for including us!
Genetic Engineering & Biotechnology News
@GENbio
GEN's new A-List is ranked by total capital raised -- Top 10 Immuno-Oncology Startups of 2019: www.genengnews.com/a-lists/top-10-immuno-oncology-startup…
-
BioNTech SE
@BioNTech_Group
Read more about our #cmo Özlem Türeci in @endpts special report on 20 extraordinary #women in #biopharma. Özlem is one of many women at #biontech who support our vision.
Endpoints News
@endpts
"Cancer immunotherapy was not an accepted pharmaceutical concept. But we stuck to that and positioned ourselves at a spot where, years later, the ball hit the ground. Do not give up, stick to the vision.” (Labiotech) Özlem Türeci @BioNTech_Group
endpts.com/special-report-twenty-extraordinary-women-in-b… -
BioNTech SE
@BioNTech_Group
Proud to be named company of the year at this year’s @LSXLeaders #lifestarawards, big thanks to the BioNTech family!
LSX Leaders
@LSXLeaders
@lifestarsawards Biotech Company of the Year WINNER! @BioNTech_Group. Congratulations to you! Plus, many thanks to our Category sponsor @MSDintheUK #lifestarsawards #biotech #medtech
-
BioNTech SE
@BioNTech_Group
Congrats to our CEO Ugur on receiving the #lifestaraward in the category private CEO of the year from @LSXLeaders
LSX Leaders
@LSXLeaders
@lifestarsawards Private CEO of the Year WINNER! Ugur Sahin, CEO, @BioNTech_Group. Congratulations to you! Plus, many thanks to our Category sponsor @Jefferies #lifestarsawards #biotech #medtech
-
BioNTech SE
@BioNTech_Group
Today we announced our third quarter financial report, the first as a public company, detailing our progress for the year to date. Looking for the full report? Click here: investors.biontech.de/financials/overview #individualizedmedicine #cancer
-
BioNTech SE reposted
Cormac Sheridan
@Cormac_Sheridan
"We're a Germany company. We think long-term." Sean Marett @BioNTech_Group #bioeurope
-
BioNTech SE reposted
Labiotech.eu
@Labiotech_eu
“Anyone who tells you that building a biotech company in Europe is easy is mistaken.” — Sean Marett, COO of @BioNTech_Group at the panel: "Funding Trends and How to Break Them" #bioeurope
-
BioNTech SE
@BioNTech_Group
We are excited to announce the launch of our new website. We believe that our approach to treating cancer is unique. So is BioNTech as a company. Hence, our employees represent the face(s) of our new website. Take a look at: biontech.de
-
BioNTech SE
@BioNTech_Group
We are proud to announce that BioNTech is now officially @Nasdaq. This is an important step on our journey to individualize cancer medicine globally. #biontechipo $BNTX
-
BioNTech SE
@BioNTech_Group
It’s official! First day of trading begins for $BNTX on Thursday, October 10th at 9:30am ET (3:30pm CET) #biontechipo
Nasdaq Exchange
@NasdaqExchange
We're thrilled to welcome @BioNTech_Group to the Nasdaq family today! We're inspired by their dedication to using technology to develop pioneering therapeutics for cancer and beyond. #biontech
-
BioNTech SE
@BioNTech_Group
We are excited to announce the closing of a $325M #seriesb round, one of the largest private #financing events for a #european #biotech company to advance our #individualized #cancer medicine pipeline. #digitaltransformation #ai See full press release here:www.biontech.com/int/en/home.html
-
BioNTech SE reposted
Labiotech.eu
@Labiotech_eu
Fireside chat with VP Business Alliances Holger Kissel of @BioNTech_Group - "How to close a high-value drug development deal?" #insiderday #biotech
-
BioNTech SE
@BioNTech_Group
BioNTech CBO/CCO, Sean Marett, is featured on our collaborator's @Roche website discussing advances in the #cancer-immunity cycle. Click here to read about how together we are individualizing #cancercare with innovative vaccines & technology: www.roche.com/stories/partnering-to-drive-innovation-in-c…
-
BioNTech SE
@BioNTech_Group
We are delighted to announce the initiation of the #firstinhuman Phase I/IIa study with #bispecific #antibody DuoBody®-PD-L1x4-1BB in #solidtumors. It is the 1st candidate from our collaboration with @Genmab to enter the clinic after only 4 years. www.biontech.com/int/en/home.html
-
BioNTech SE
@BioNTech_Group
Today we announced the acquisition of MabVax Therapeutics’ #antibody assets to expand our portfolio. See here for the full announcement: www.biontech.com/int/en/home.html
-
BioNTech SE
@BioNTech_Group
Thank you at @techreview @BillGates for including us in the 10 breakthrough technologies of 2019! We are committed to bringing individualized cancer immunotherapies into clinical application. More on our approach here: www.biontech.com/int/en/home.html
MIT Technology Review
@techreview
Each year, we pick 10 breakthroughs we think will make a big impact in the near future. This year, we decided to ask someone for help.
www.technologyreview.com/lists/technologies/2019/ -
BioNTech SE
@BioNTech_Group
We are delighted to announce that our CEO, Ugur Sahin was awarded the German Cancer Award 2019 by @DKG_Berlin, one of the most prestigious awards in #cancer medicine in Germany. Read the full announcement here:www.biontech.com/int/en/home.html
-
BioNTech SE
@BioNTech_Group
We have entered into an agreement to acquire MAB Discovery’s antibody generation unit. This follows a successful collaboration with MAB Discovery in which antibodies were generated w/ MAB Discovery’s proprietary technology for further development by BioNTech.
-
BioNTech SE
@BioNTech_Group
We also extend a warm welcome to Ryan Richardson who will join our team as Senior VP Corporate Development & Strategy & Dr. Ulrich Wandschneider who has been appointed as a member of the SAB. We look forward to collaborating with these highly experienced industry experts.
-
BioNTech SE
@BioNTech_Group
Today we announced we are undergoing a corporate transition from AG to SE. The transition will enable greater flexibility to operate globally and engage in fund-raising transactions & partnerships with other international corporations. www.biontech.com/int/en/home.html
-
BioNTech SE
@BioNTech_Group
Today we announced that we have extended our research collaboration w/ @sanofi & that Sanofi is investing $91.5m (€80m) in equity. This partnership will support the advancement of mRNA-based cancer immunotherapy into clinical testing against multiple solid tumors.
-
BioNTech SE
@BioNTech_Group
Wishing everyone a wonderful holiday season and a great start in the new year!
-
BioNTech SE
@BioNTech_Group
.@nature has published trial data demonstrating proof-of-concept of the @GAPVAC approach against glioblastoma. The results of this highly personalized method provide promise for the future of immunotherapy: gapvac.eu/news/ #gapvac #cancer #vaccine
-
BioNTech SE
@BioNTech_Group
.@GAPVAC published the first-in-human trial of a novel actively personalized therapeutic vaccine for #braincancer in @nature. BioNTech used its next-generation sequencing expertise to identify immunogenic tumor mutations & to generate a blueprint for the personalized #vaccine.
-
BioNTech SE
@BioNTech_Group
Join us today @SABCSSanAntonio for our MammaTyper® poster presentations:
1. “Comparison of RT-qPCR with consensus immunohistochemistry by three pathologists for ER, PR,HER2 and Ki-67 in Chinese breast cancer patients”...
BioNTech SE
@BioNTech_Group
...& 2. “MammaTyper® - An in vitro quantitative local gene expression test as predictor of OncoType DX® - and EndoPredict® results” from 7.00 - 9.00 AM CST, Hall 1 #sabcs18!
-
BioNTech SE
@BioNTech_Group
Get an update on BioNTech from our CBO/CCO, Sean Marett who had the opportunity to be interviewed by @ScripMikeWard during #bioeurope2018. Sean gave more background on BioNTech’s move into #infectiousdiseases & recent related deals w/ @pfizer & University of Pennsylvania
EBD Group
@EBDgroup
German mRNA-focused biotech #biontech is branching out from its immuno-oncology focus to explore the potential of its platforms in infectious diseases. CBO and CCO, Sean Marett, reveals how deals signed in the second half of 2018 informaconnect.com/biontech-cbo-outlines-infectious-disea… @ScripMikeWard #bioeurope
-
BioNTech SE
@BioNTech_Group
We are pleased to have been included in @Labiotech_eu’s overview on ‘How to Turn Your Biotech Startup into a Successful Company.’ See the full article here: labiotech.eu/sponsored/guide-biotech-startup-successful-c…
-
BioNTech SE
@BioNTech_Group
Join us @SABCSSanAntonio for our MammaTyper® poster presentations, “Standardized prediction of OncoType DX® risk classes by local RT-qPCR” on Thursday from 7.00 - 9.00 AM CST, Hall 1, #sabcs18!
-
BioNTech SE
@BioNTech_Group
Sean Marett, our CBO/CCO has been invited to be a panelist on the RNA panel titled, ‘The year of RNA and the start of a new era.’ The panel is 1 out of 6 at the 2019 #biotechshowcase that is highlighted as a #therapeutic area garnering attention for investment in 2019
EBD Group
@EBDgroup
#biotechshowcase has assembled panels of high caliber speakers to discuss how advancements and investment in these areas will change the future of healthcare. #pressrelease highlights the therapeutic areas in this year agenda >> www.ebdgroup.com/biotech-showcase-highlights-six-therapeu… @Demy_Colton
-
BioNTech SE
@BioNTech_Group
Join us @SABCSSanAntonio for our poster presentation, "Highly innovative personalized RNA-immunotherapy for patients with triple negative breast cancer" on Thursday, December 6th from 5.00 - 7.00 PM, Hall 1 #sabcs18!
-
BioNTech SE
@BioNTech_Group
Our CBO/CCO, Sean Marett had the opportunity to be interviewed by @ScripMikeWard during #bioeurope2018. Sean gave more background on BioNTech’s move into #infectiousdiseases & recent related deals w/ @pfizer & University of Pennsylvania. www.youtube.com/watch?v=qdwg7alEmnY
-
BioNTech SE reposted
Scrip, Citeline Commercial
@PharmaScrip
The Private Financing Deal of the Year goes to BioNTech's $270m Series A Financing. Congratulations! #scripawards2018
-
BioNTech SE
@BioNTech_Group
We are honored to have been awarded the Financing Deal of the Year 2018 at the #scripawards in London last night. Thank you to @Pharma_Intell for the brilliant event & congrats to the full BioNTech team for all the hard work & fantastic progress made in 2018.
-
BioNTech SE
@BioNTech_Group
BioNTech is excited to join in the conversation around #mrna, #individualized immunotherapies and #biotech on Twitter. Keep an eye out for upcoming corporate announcements and news!


























































































































































































































































